跳转至内容
Merck
CN

SML0132

醋酸兰瑞肽

≥98% (HPLC), SRIF-1 sst2 subtype of somatostatin receptor agonist, powder

别名:

3-(2-萘基)-D-丙氨酰基-L-半胱氨酰基-L-酪氨酸-D-色氨酸-L-赖氨酰基-L-戊酰基-L-半胱氨酰-L-苏氨酸酰胺环状(2→7)-乙酸二硫, BIM-23014C, 醋酸血管肽素

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C54H69N11O10S2 · xC2H4O2
化学文摘社编号:
127984-74-1
分子量:
1096.32 (free base basis)
UNSPSC Code:
12352200
PubChem Substance ID:
329825182
NACRES:
NA.25

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

醋酸兰瑞肽, ≥98% (HPLC)

form

powder

SMILES string

CC(O)=O.CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@H](N)Cc5ccc6ccccc6c5

InChI

1S/C54H69N11O10S2.C2H4O2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55;1-2(3)4/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74);1H3,(H,3,4)/t30-,38-,40+,41+,42-,43+,44?,45+,46+;/m1./s1

InChI key

DEXPIBGCLCPUHE-HPDHVNDUSA-N

assay

≥98% (HPLC)

color

white to off-white

shipped in

wet ice

storage temp.

−20°C

Quality Level

100

相关类别

Application

乙酸兰瑞肽已被用作抑制剂，以测试野生型小鼠中生长激素/甲状腺激素信号转导对硫化氢调节的可变性。

Biochem/physiol Actions

八肽生长抑素类似物；sst2生长抑素受体激动剂；抗肿瘤
醋酸兰瑞肽是一种生长抑素类似物，是生长抑素受体SRIF-1 sst2亚型的选择性激动剂，对sst2的结合亲和力为0.8 nM，对sst5的结合亲和力为5.2 nM，对sst3的结合亲和力为100 nM，对于SRIF-2亚型sst1和sst4受体的结合亲和力为1000 nM以上。它在临床上可用于肢端肥大症和神经内分泌肿瘤所引起的症状的治疗，并且在最近的研究中还可以用于抑制肿瘤的生长，并显示出对非内分泌肿瘤的活性。

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H361

pcodes

P281

Hazard Classifications

Repr. 2

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

涉药品监管产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000482799
0000482779
0000482799
0000482779
0000424559

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Peter Kühnen et al.
Hormone research in paediatrics, 78(2), 106-112 (2012-08-22)
Medical treatment is a substantial therapeutic measure to achieve glycemic control and prevent hypoglycemic brain damage without surgery in patients with congenital hyperinsulinism (CHI). However, only few drugs are available and even fewer are approved as a medical therapy to
Jonathan R Strosberg et al.
Pancreas, 42(3), 397-404 (2012-12-06)
This study aimed to develop expert consensus for the use of systemic treatments for unresectable metastatic well-differentiated (grade 1-2) carcinoid tumors using the RAND/UCLA modified Delphi process. After a comprehensive literature review, 404 patient scenarios addressing the use of systemic
Giovanni Vitale et al.
The Journal of clinical endocrinology and metabolism, 98(10), E1567-E1574 (2013-07-26)
To date no efficacious treatments are available for advanced medullary thyroid carcinoma (MTC). We investigated in vitro and in vivo a new strategy for the therapy of MTC, combining human recombinant IL-2 with lanreotide (LAN), a somatostatin analog. The in
Omid Fotouhi et al.
The Journal of clinical endocrinology and metabolism, 101(10), 3616-3627 (2016-07-28)
Somatostatin analogs are established in the treatment of neuroendocrine tumors (NETs) including small intestinal NET; however, the molecular mechanisms are not well known. Here, we examined the direct effects of lanreotide in NET cell line models. The cell lines HC45
Anand K Annamalai et al.
The Journal of clinical endocrinology and metabolism, 98(3), 1040-1050 (2013-02-09)
Attainment of safe GH and IGF-1 levels is a central goal of acromegaly management. The aim of this study was to determine the extent to which reductions in GH and IGF-1 concentrations correlate with amelioration of radiological, metabolic, vascular, cardiac
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持